Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Gastric Reflux Drugs Could Raise Dementia Risk

By Drug Discovery Trends Editor | February 17, 2016

A study in Germany suggests that the repeated use of drugs called proton pump inhibitors (PPIs) to treat stomach ailments may raise the risk of dementia.

The researchers who conducted the trial analyzed medical records from 2004 through 2011 of 73,000 patients, mostly women, who were age 75 or older, reports Reuters. A total of 2,950 patients were labeled as regular PPI users, which meant they filled one prescription for the drug every four or five months over an 18-month period .

Overall, the scientists found 29,510 people had developed dementia during the study. An estimated 44 percent had a higher chance of developing the neurological disorder compared with patients who weren’t taking these medications.

Senior author Britta Haenisch told Reuters the research team was only able to provide, “statistical association between PPI prescriptions and occurrence of dementia in the elderly,” but couldn’t prove PPIs were the direct cause.

Furthermore, the team didn’t know if certain individuals they looked at were already at risk for dementia. The research was published in the journal JAMA Neurology.

Other studies have said PPIs are linked to an increased risk of chronic kidney disease or heart conditions.  PPIs are taken by an estimated 15 million Americans, according to NPR


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50